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Abstract
Glucocorticoid excess increases fat mass, preferentially within
omental depots; yet circulating cortisol concentrations are
normal in most patients with metabolic syndrome (MS). At a
pre-receptor level, 11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) activates cortisol from cortisone locally within
adipose tissue, and inhibition of 11b-HSD1 in liver and
adipose tissue has been proposed as a novel therapy to treat
MS by reducing hepatic glucose output and adiposity. Using a
transformed human subcutaneous preadipocyte cell line
(Chub-S7) and human primary preadipocytes, we have
deﬁned the role of glucocorticoids and 11b-HSD1 in
regulating adipose tissue differentiation. Human cells were
differentiated with 1.0 mM cortisol (F), or cortisone (E) with
or without 100 nM of a highly selective 11b-HSD1 inhibitor
PF-877423. 11b-HSD1 mRNA expression increased across
adipocyte differentiation (P!0.001, nZ4), which was
paralleled by an increase in 11b-HSD1 oxo-reductase activity
(from nil on day 0 to 5.9G1.9 pmol/mg per h on day 16,
P!0.01, nZ7). Cortisone enhanced adipocyte differen-
tiation; fatty acid-binding protein 4 expression increased 312-
fold (P!0.001) and glycerol-3-phosphate dehydrogenase
47-fold (P!0.001) versus controls. This was abolished by
co-incubation with PF-877423. In addition, cellular lipid
content decreased signiﬁcantly. These ﬁndings were
conﬁrmed in the primary cultures of human subcutaneous
preadipocytes. The increase in 11b-HSD1 mRNA expression
and activity is essential for the induction of human
adipogenesis. Blocking adipogenesis with a novel and speciﬁc
11b-HSD1 inhibitor may represent a novel approach to treat
obesity in patients with MS.
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Introduction
Glucocorticoid excess (Cushing’s syndrome) causes visceral
obesity, insulin resistance, diabetes mellitus, dyslipidaemia,
hypertension and premature vascular mortality; as such it
representsanexcellentparadigmfor patientswiththemetabolic
syndrome (MS). However, Cushing’s syndrome is rare and
circulating glucocorticoid levels are usually normal or even
slightlyreducedinobesepatients(Fraseretal.1999).Atacellular
level, glucocorticoids within human adipose tissue, speciﬁcally
in omental depots, can be generated from inactive circulating
cortisone(inhumans)or11-dehydrocorticosterone(inrodents)
through the oxo-reductase activity of 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1; Bujalska et al.1 9 9 7 b).
Transgenic mice with adipose tissue-targeted 11b-HSD1
overexpression develop visceral obesity, insulin resistance,
hyperlipidaemia and hypertension without altering circulating
glucocorticoids (Masuzaki et al.2 0 0 1 , 2003), while mice with
11b-HSD1 overexpression in the liver develop MS without
obesity (Paterson et al.2 0 0 4 ). Conversely, global deletion of
11b-HSD1 caused reduced visceral fat accumulation and
improved insulin sensitivity on a high fat diet (Kotelevtsev
et al. 1997, Morton et al. 2004). At a molecular level,
glucocorticoids exert potent effects upon adipose tissue; in
mature rat adipocytes,dexamethasonedecreases glucoseuptake
and oxidation (Olefsky 1975, De et al.1 9 8 1 ). Glucocorticoids
increase lipolysis by up-regulating the expression of the rate-
limitingenzymehormone-sensitivelipase(Slavinet al.19 94 ), as
wellaslipogenicenzyme,lipoproteinlipase(Yang etal.1993).In
preadipocytes, glucocorticoids are essential for terminal
adipogenesis (Hauner et al.1 9 8 7 ) and limit cell proliferation
(Tomlinson etal.2002).Theprocessofcellulardifferentiationisa
highly synchronized cascade of regulated differentiation-
dependent gene expression. Genes such as retinoblastoma
proteins that regulate the cell cycle (Richon et al.1 9 9 7 )
are followed by adipogenic transcription factors, such as
peroxisome proliferator-activated receptor g (PPARg)a n d
CCAAT enhancer-binding protein (Rosen & MacDougald
2006). Mature adipocytes express late differentiation genes
involved in lipid metabolism and lipid transport including
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binding protein 4 (FABP4; Hotamisligil et al.1 9 9 6 ); many of
these genes are regulated by glucocorticoids (Wu et al.1 9 9 6 ,
Rosen & MacDougald 2006). Previously, we have shown that
non-selective inhibition of 11b-HSD1 can prevent human
adipocyte differentiation in vitro (Bujalska et al.1 9 9 9 ). The
potential for therapeutic intervention has been tested in rodent
models where selective 11b-HSD1 inhibitors lower plasma
glucose, improve insulin sensitivity and in some studies reduce
body weight in mice (Alberts et al.2 0 0 2 , Kershaw et al.2 0 0 5 ).
However, the potency of these inhibitors has beenvariable and
there are no data on efﬁcacy in human tissue. We report the
developmentofaselectiveinhibitoragainsthuman11b-HSD1,
PF-877423 (Pﬁzer Global R&D, La Jolla, CA, USA) and the
effect of this compound upon adipogenesis in a well-
characterised differentiating human subcutaneous preadipocyte
cell line (Darimont et al.2 0 0 3 , Qiao et al.2 0 0 5 ) and in primary
cultures of subcutaneous human preadipocytes.
Research design and methods
Recombinant protein assay
Wild-type recombinant human 11b-HSD1 protein (24–292)
was used for studying the inhibitor kinetics. Radio-labelled
[1,2-
3H]-cortisone was purchased from American Radio-
labeled Chemicals Inc (St Louis, MO, USA). NAD (reduced
form; NADPH), glucose-6-phosphate (G6P) and G6P
d e h y d r o g e n a s e( G 6 P D )w e r ep u r c h a s e df r o mS i g m a –
Aldrich. All the concentrations reported in the following
section are ﬁnal in the assay buffer. In addition, the enzyme
concentrations represent the active concentrations that were
determined by active-site titration using a tight-binding
inhibitor. The experimental data were ﬁtted by using the
non-linear regression analysis software, Graﬁt (Leather-
barrow (2001) GraFit Version 5, Erithacus Software Ltd,
Horley, UK).
The measurement of the in vitro 11b-HSD1 activity was
performed in a 100 mM triethanolamine buffer (pH 8.0),
containing 200 mM NaCl, 0.02% n-dodecyl b-D-maltoside,
5% glycerol and 5 mM b-mercaptoethanol. A typical
reaction for the determination of enzyme activity comprised
the following: 5 nM enzyme pre-incubated for at least
30 minutes in the assay buffer in the presence of 500 mM
NADPH in round-bottom 96-well plates (Costar cat #
3365). Next, the reaction was initiated by adding a
regenerating system (consisting of 2 mM G6P, 1 U/ml
G6PD and 6 mM MgCl2) and labelled
3H-cortisone as
substrate. After an incubation period (30–40 min), 100 ml
of the assay mixture were transferred to a second empty
round-bottom 96-well plate and mixed with an equal
volume of dimethylsulphoxide (DMSO) to quench the
reaction. Then, a 15 ml aliquot of the assay solution was
loaded into a C-18 column (Polaris C18-A, 50!4. 6 mm,
5 u, 180 A ˚, Varian; Polaris, Palo Alto, CA, USA connected
to an automated High-Throughput Liquid Chromatography
instrument (Cohesive Technologies, HTLC, Franklin, MA,
USA). The radioactive material from the column was
detected with a b-RAM model 3 Radio-HPLC detector
(IN/US, Tampa, FL, USA). Substrate and product peaks
were separated by using an isocratic mixture of 38:62
methanol to water (v/v) at a ﬂow rate of 1. 0 ml/min. Under
these experimental conditions, the retention time for
cortisone and cortisol were 4.5 and 5.5 min respectively.
The initial reaction velocities recorded were in the linear
range and were determined by measuring the peak area for
cortisol formation with time.
Recombinant protein kinetic analysis
The inhibition of 11b-HSD1 by PF-877423 was analysed
by ﬁtting to the equation described below (Equation
(1); Morrison 1969) and provided an accurate measure-
ment for the value of Kiapp at a ﬁxed concentration of
cortisone
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where [E]o and [I]o are the active enzyme and inhibitor
concentration respectively; Vi and Vo are the rates of
cortisone reduction in the presence or in the absence of
inhibitor respectively. Four Kiapp values were determined
by varying the cortisone concentration while keeping
the concentration of NADPH constant at 500 mMi n
the assay buffer. The true inhibition constant, Ki, for
PF-877423 was then obtained by plotting the Kiapp
values versus the cortisone concentration, [C]o, and
ﬁtting the data using Equation (2) for a competitive
inhibitor
Kiapp ZKi 1C
½C o
Km
  
(2)
where Km was the Michaelis–Menten constant for
cortisone.
HEK293 and Chubb-S7 cell culture
HEK293 cells stably transfected with human 11b-HSD1
(HEK293T1) or 11b-HSD2 (HEK293T2) cDNA as
described previously (Bujalska et al. 1997a) were used to
study the speciﬁcityof inhibitor PF-877423 upon 11b-HSDs.
Cells were cultured in minimum essential medium (MEM)
media supplemented with 10% fetal bovine serum (FBS) and
1% non-essential fatty acids; for experiments, cells were
seeded into 24-well tissue culture dishes and maintained in
MEM with 10% FBS until conﬂuence.
The Chub-S7 cell line was derived from human subcu-
taneousadiposetissue(Darimontetal.2003)byco-expressionof
human telomerase reverse transcriptase and papillomavirus E7
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spanandthecapacitytoaccumulatelipidwithoutchromosomal
alteration. Conﬂuent Chub-S7 cells were cultured in 75 cm
2
TC ﬂasks in DMEM/Ham’s F-12 medium supplemented
with 10% FBS. For experiments, cells were seeded in 24-well
platesatdensity10
5cells/well.Chub-S7weredifferentiated(up
to 21 days) according to Hauner et al. (1987) with 166 nM
human insulin (I-9278 Sigma), 1 mMP P A R g agonist
(GW1929, Camlab, Cambridge, UK) and, where speciﬁed,
with the addition of 1 mM cortisol (F). For inhibition studies,
Chub-S7 cells were differentiated with 0.5 mM cortisone (E)
and an optimised concentration of the selective 11b-HSD1
inhibitor, PF-877423, at a ﬁnal concentration of 100 nM.
Human subcutaneous stromal-vascular cell differentiation
Conﬂuent human subcutaneous stromal-vascular (s–v) cells
(96-well plates) were obtained from Zen-Bio Inc. (Research
Triangle Park, NC, USA) and allowed to recover overnight at
37 8C5 %C O 2. The following day, day 0, differentiation was
initiated by incubating cells in differentiating media, DM2(E)
(Zen-Bio Inc.), which consists of DMEM/Ham’s F-12
medium containing FBS, L-glutamine, penicillin/streptomy-
cin, insulin, indomethacin, 3-isobutyl-1-methylxanthine
with 1 mM E and vehicle (DMSO not exceeding 0.1%). To
deﬁne the effect of the PF-877423 inhibitor upon the
differentiation of primary preadipocytes, cultures were
supplemented with 300 nM PF-877423 (in DMSO). Control
cells cultured without E. Media were replenished and
PF-877423 or vehicle treatment repeated every 2–3 days,
except when 11b-HSD1 activity was assessed.
Measuring lipid content in human subcutaneous s–v cells
Lipogenesis in human subcutaneous s–v cells was measured as
triglyceride accumulation. Cells were carefully washed with
PBS and lysed in situ by adding 50 ml/well of Hecameg (10%
solutioninwater–Calbiochem,Nottingham,UK).Aftergentle
shaking at room temperature for 10 min, 200 mlt r i g l y c e r i d e
(Inﬁnity) reagent (Thermo DMA, Louisville, CO, USA) was
added to each well. Plates were read after 10–20 min at
500 nm with correction at 660 nm (Spectra MAX PLUS –
Molecular Devices Corporation, Sunnyvale, CA, USA).
Results were expressed as optical density (OD) values.
HEK293 and Chubb-S7 11b-HSD assay
Cells were washed and incubated with 100 nM F (for
dehydrogenase activity) or E (for oxo-reductase activity) with
appropriatetritiatedtracer–
3HF(DuPont,Stevenage,UK)or
3HE( 0 .02 mCi/reaction; Bujalska et al.1 9 9 9 ). PF-877423
speciﬁcityupon11b-HSD1wascarriedoutwiththeadditionof
100 nM inhibitor to HEK293T1 and HEK293T2 cells 24 h
before and during the enzyme assay. After 3 h incubation with
substrate, media was removed and steroids extracted with 4 ml
dichloromethane, evaporated under the air and reconstituted
with 70 ml dichloromethane, then spotted on silica plates
(Sigma–Aldrich).Steroidswereseparatedbythin-layerchroma-
tography in chloroform and ethanol (92:8) and steroid
conversion was quantiﬁed using a LabLogic AR-200 scanner
(LabLogic, Shefﬁeld, UK). Cells were washed and protein
concentration was measured using colorimetric 96-well plate
assay (Bio-Rad) and total RNAwas extracted.
Human subcutaneous s–v cells 11b-HSD1 assay
During 11b-HSD1 activity assessment in human subcutaneous
s–v cells, the medium was changed to basal medium (BM-1,
Zen-BioInc.)containingonlyantibiotics,andcellswerecultured
for 24 h in the presence of PF-877423 with or without 0.5 mM
E. At the end of the incubation, the cortisol signal was
quantitatively determined in the 100 ml cell supernatant with
the Correlate-EnzymeImmunoassay Cortisolkit(AssayDesigns
Inc. Ann Arbor, MI, USA) following the manufacturers’
instructions. Plates were read on a plate reader (Spectra MAX
PLUS – Molecular Devices Corporation) at 405 nm, with
correction at 580 nm. Activity has been expressed as cortisol
production in pg/ml per 24 h.
Total RNA extraction and RTreaction
Total RNA was extracted from cells using TriReagent
(Sigma) according to the manufacturer’s protocol. Integrity
and concentration of RNA were assessed by electrophoresis
and spectrophotometry respectively. Reverse transcription
was carried out using AMVand random primers at 37 8C for
1 h. All RT reagents were purchased from Promega.
PCR
Expression studies were carried out using gene speciﬁc primers
for human 11 b-HSD1, hexose 6-phosphate dehydrogenase
(H6PDH), glucocorticoid receptor a (GRa, FABP4), G3PD,
glucose transporter 4 (GLUT-4) and PPARg. All primers were
designedusingprimer3software(http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3.cgi)andtheir sequences from50 to30 are
shown in Table 1. Primers for 18S as internal control were
purchased from Ambion (Quantum RNATM Classic 18S
Internal Standard #1716; Ambion). PCRs were carried out at
95 8C for 30 s, 60 8C for 30 s and 72 8C for 30 s in 20 ml ﬁnal
volume for 30 cycles.
Real-time PCR
QuantitativemRNA expressionlevels of11b-HSD1, H6PDH,
GRa,FABP4,G3PD ,GLUT -4andPP ARg2weremeasuredby
real-time PCR using an ABI 7500 system (Perkin–Elmer,
Biosystems, Warrington, UK). PCR was performed in 25 ml
reactions on 96-well plates. Reactions contained TaqMan
universal PCR master mix (Applied Biosystems, Foster City,
CA, USA), 900 nmol primers, 100–200 nmol TaqMan probe
and25–50 ngcDNA.Allreactionswerecorrelatedtoexpression
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Perkin–Elmer) as an internal reference. All target gene probes
werelabelledwiththeﬂuorescentlabelFAMandthe18Sprobe
withtheﬂuorescentlabelVIC.Reactionswereasfollows:50 8C
for2 min,95 8Cfor10 min,andthen40cyclesof95 8Cfor15s
and 60 8C for 1 min. Data were analysed according to the
manufacturer’s guidelines and were obtained as Ct values (the
cyclenumberatwhichlogarithmicPCRplotscrossacalculated
thresholdline)andusedtodeterminedCtvalues(dCtZCtofthe
targetgeneminusCtoftheinternalreference,18S).Primersand
probesfor11b-HSD1,H6PDHandG3PDweredesignedusing
PrimerExpress 1.0 software (Applied Biosystems). Sequences
from 50 to 30 are shown in Table 2. Expression assay kits were
purchased from Applied Biosystems to measure the gene
expression of GRa,G L U T - 4 ,P P A R g2a n dF A B P 4 .
Statistical analysis
Wheredatawerenormallydistributed,unpairedStudent’st-test
wasusedtocomparesingletreatmentswithcontrol.Ifnormality
tests failed, then non-parametric tests were used. One-way
ANOVA on ranks was used to compare multiple treatments
(SigmaStat 3.1, Systat Software Inc., Point Richmond, CA,
USA). Results were expressed as mean valuesGS.D.o rS.E.M.
values and a P value of !0.05 was accepted as statistically
signiﬁcant. Statistical analysis on real-time PCR data was
performed on mean DCt values and not on fold changes.
Results
Kinetics of PF-877423 upon recombinant 11b-HSD1 protein
The potency for PF-877423 was strongly affected by the
presence of the substrate in the assay buffer (Fig. 1): K
app
i
values increased at high cortisone concentration, suggesting
that the inhibitor behaved as a reversible and competitive
inhibitor against cortisone. Fitting the experimental data
using equation (2) provided avalue of 0.2G0.04 and 333.4G
109.2 nM for the inhibition constant, Ki, and the apparent
Michaelis–Menten constant, Km respectively.
Speciﬁcity of PF-877423
11b-HSD enzyme assays on HEK293T1 and HEK293T2 cells
showed total abolition of dehydrogenase (12.4G1.0v s0 .2G
0.01, % cortisol to cortisone conversion, meanGS.D.) and oxo-
reductase (34.7G0.6v s0 .4G0.1, % cortisone to cortisol
conversion, meanGS.D.) activities of 11b-HSD1 following
incubation with 100 nM PF-877423 for 24 h (Fig. 2A), but
PF-877423 had no effect on 11b-HSD2 activity (63.6G4.0v s
62.2G4.4, % cortisol to cortisone conversion, meanGS.D.,
control versus PF-877423 respectively; Fig. 2B). No toxic
effectsofPF-877423wereobservedupto10 mMconcentrations
using a commercially available assay kit (CellTiter 96 Aqueous,
Promega; data not shown).
Table 1 Primer sequences for various human genes for the PCR
Forward Reverse
Gene
HSD11B1 ACCAGAGATGCTCCAAGGAA ATGCTTCCATTGCTCTGCTT
H6PDH AGAAGCGAGACAGCTTCCAC GCTGCTGGGAAAAGAACAAC
GRa TCGACCAGTGTTCCAGAGAAC TTTCGGAACCAACGGGAATTG
GLUT-4 GCCATTGTTATCGGCATTCT CTACCCCTGCTGTCTCGAAG
PPARg1 TCTCTCCGTAATGGAAGACC GCATTATGAGACATCCCCAC
PPARg2 GCGATTCCTTCACTGATAC GCATTATGAGACATCCCCAC
G3PD GGAAGACATTGGAGGCAAAA CCACGGCCACTACATTCTTT
FABP4 CATCAGTGTGAATGGGGATG ATGCGAACTTCAGTCCAGGT
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3).
Table 2 Primer and probe sequences for various human genes for the real-time PCR
Forward Reverse Probe
Gene
HSD11B1 AGGAAAGCTCATGGGAGGACTAG ATGGTGAATATCATCATGAA AAAGATTC CATGCTCATTCTCAACCACATCA CCAACA
H6PDH GGGCCTATGGAACCTCCAA GACCCACGTTTCTCACTGAC TCT CCGTGGCGCTACTCATGGACAC A
PPARg2 AGAAGAAGGCGGCGTTGTC TCAGGTTGAGGCCACCATC AGGGGCCACCACAGACTTGCAC AT
G3PD CCATCAGTTCATCGGCAAGAT TCGTCTACCCCCTTAATAAG AGATATG AGGGCCATCTGAAGGCAAACGC C
Primers and probes were designed using PrimerExpress software (Applied Biosystems, UK).
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At conﬂuence (day 0), Chub-S7 cells did not accumulate lipid
droplets (Fig. 3A); however, they readily underwent adipogen-
esis (shown as oil red O staining) when cultured for 21 days in
chemically-deﬁned, serum-free media (166 nM insulin, 1 mM
PPARg agonist and 1 mMF ;Fig. 3B). As demonstrated
by conventional PCR, conﬂuent undifferentiated Chub-S7
cells expressed GRa H6PDH and PPARg1 mRNA but not
11b-HSD1, PPARg2, GLUT-4, G3PD or FABP4 mRNA
(Fig. 3C). In the differentiated Chub-S7 cells, increased
expression of adipogenic markers including G3PD and
FABP4 was observed. This process resulted in an increase in
11b-HSD1, GLUT-4 and PPARg2m R N Al e v e l s( Fig. 3D).
Across differentiation, 11b-HSD1 oxo-reductase activity
increased signiﬁcantly; from nil on day 0 to 0.4G0.2o nd a y
3, 5.3G0.7 on day 5, 8.4G0.14 on day 7, 10.5G1.9o nd a y9
and 5.9G1.9 onday 16 (pmol/mg per h, meanGS.D., nZ7, all
P!0.01 versus previous time point; Fig. 4A). Conventional
PCRﬁndingswereendorsedandquantiﬁedbyreal-timePCR.
Expression of 11b-HSD1 mRNA increased 2.9-fold on day 5,
3.6-foldonday7,3.4-foldonday9(P!0.01)and38.1-foldon
day 16 (P!0.001) when compared with day 3, nZ4( Fig. 4B).
We observed a transient increase in H6PDH mRNA levels
(11b-HSD1 co-factor provider) – 2.9-fold on day 3, 3.5-fold
on day 5, 3.7-fold on day 7, 3.4-fold on day 9 and 0.6-fold
on day 16 versus day 0, P!0.01 (Fig. 4C) – but there was no
signiﬁcant change in GRa mRNA during Chub-S7
differentiation (Fig. 4D).
SigniﬁcantincreasesindifferentiationmarkersFABP4(2-fold
on day 5 (P!0.01), 38-fold on day 7, 142-fold on day 9 and
870-foldonday16versusday3,P!0.001)andG3PD(4.5-fold
on day 7 (P!0.01), 22-fold on day 9 and 380-fold on day 16
versus day 5, P!0.001) were also observed (Fig. 5A and B
respectively). When compared with day 7, the expression of
adipocyte-speciﬁc genes including GLUT-4 and PPARg2a l s o
increased – 2.1-fold on day 9 and 9.8-fold on day 16, P!0.01
(GLUT-4) and 1.3-fold on day 7 and 2.2-fold on day 16,
P!0.01 (PPARg2; Fig. 5C and D respectively).
Glucocorticoid metabolism and adipogenesis in Chub-S7 cells
incubated with PF-877423
Chub-S7 cells differentiated for 10 days with 500 nM
cortisone showed increased 11b-HSD1 oxo-reductase
activity: 14.6G2.3 (E) versus 3.4G1.3 (control), pmol/mg
per h meanGS.E.M., P!0.001 (Fig. 6A), and mRNA
expression (14.1-fold versus control; Fig. 6B). Co-incubation
with 100 nM PF-877423 abolished this effect: 14.6G2.3 (E)
versus 1.3G1.1( E CPF-877423) vs 0.6G0.5 (PF-877423)
pmol/mg per h, meanGS.E.M.( Fig. 6A) and 14.1-fold (E)
versus 1.2-fold (ECPF-877423), 11b-HSD1 activity and
mRNA respectively (Fig. 6B). Differentiated Chub-S7 cells
with E showed increased expression of the adipogenic
markers FABP4 (312-fold versus control, P!0.001) and
G3PD (47-fold versus control, P!0.001) – an effect that was
completelyabolished by co-incubation with PF-877423 (1.3-
and 0.7-fold, FABP4 and G3PD respectively; Fig. 6C and D).
The change in adipogenesis following incubation with the
11b-HSD1-speciﬁc inhibitor was conﬁrmed visually through
staining the cellswith oil red O after 21 days of differentiation.
A marked increase in the number of red-stained cells was
observed in cells differentiated with E or F but not in the
presence of PF-877423 (Fig. 6E).
Figure 1 Effect of cortisone concentration upon the apparent
inhibition constant Kiapp of the inhibitor PF-877423: a value for
the true inhibition constant Ki (0.2G0.04 nM) and the Michaelis–
Menten constant Km (333.4G109.2 nM) is calculated by ﬁtting the
experimental data using equation (2).
Figure 2 (A) PF-877423 inhibits 11b-HSD1 enzyme activity
(dehydrogenase: 12.4G1.0v s0 .2G0.01, % cortisol to cortisone
conversion, andoxo-reductase:34.7G0.6vs0.4G0.1,% cortisone
to cortisol conversion, meanGS.D.) as measured in HEK293T1
(HEK293 cells stably transfected with human 11b-HSD type 1
cDNA), nZ3 but not (B) 11b-HSD2 enzyme activity (63.6G4.0v s
62.2G4.4, % cortisol to cortisone conversion, meanGS.D., control
versus PF-9Z877423 respectively) as measured in HEK293T2 (cells
stably transfected with human 11b-HSD type 2 cDNA), nZ3.
P values: **P!0.01, ***P!0.001.
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Human subcutaneous s–v cells differentiated with ECPF-
877423 had signiﬁcantly lower 11b-HSD1 oxo-reductase
activity compared with cells differentiated with E at any time
point studied (day 6: 154G8 vs 5387G182; day 9: 128G1v s
5489G230; day 14: 174G18 vs 4041G106; day 20: 409G27
vs10443G78;day22:330G7vs11218G193 pg/mlper24 h,
meanGS.D., P!0.001, nZ3, EK or ECPF-877423 treated
respectively (Fig. 7A)). Lipid content in cells differentiated
with E and PF-877423 was signiﬁcantly lower than in cells
differentiated with E only and similar to undifferentiated cells
(day 16, 0.25G0.03 vs 0.20G0.01; day 20, 0.3G0.02 vs
0.20G0.01; day 22, 0.27G0.01 vs 0.19G0.01; OD (500/
660 nm); meanGS.D., P!0.01, nZ3, EK or ECPF-877423
treated respectively; Fig. 7B).
Discussion
Numerousstudies(Hauneretal.1989,Gregoireetal.1991,Wolf
1999), including our own (Bujalska et al.1 9 9 9 , 2002b), have
Figure 3 Oil red O staining in (A) conﬂuent Chub-S7 cells (day 0) and (B) differentiated Chub-S7 (day 21). RT-PCR analysis (30 cycles) of
nine gene expressions in (C) conﬂuent Chub-S7 cells and (D) in differentiated Chub-S7 cells.
Figure 4 (A) 11b-HSD1 oxo-reductase activity (cortisone to cortisol conversion); nil on day 0 to 0.4G0.2o nd a y3 ,
5.3G0.7 on day 5, 8.4G0.14 on day 7, 10.5G1.9 on day 9 and 5.9G1.9 on day 16, pmol/mg per h, meanGS.D. versus
previous time point, nZ7 and mRNA levels measured by real-time PCR of (B) 11b-HSD1 (2.9-fold increase on day 5,
3.6-fold on day 7, 3.4-fold on day 9 and 38.1-fold on day 16 when compared with day 3). (C) H6PDH increased 2.9-
fold on day 3, 3.5-fold on day 5, 3.7-fold on day 7, 3.4-fold on day 9 and 0.6-fold on day 16 versus day 0 and (D) GRa
(no signiﬁcant change) across Chub-S7 differentiation, nZ4. P values: **P!0.01, ***P!0.001.
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differentiation. Here, we extend those observations to a novel
transformed human adipocyte cell line that should greatly
enhanceinvitrohuman-basedadipocyteresearchstudies.Within
5 days of incubation in chemically deﬁned media comprising
insulin, PPARg agonist and glucocorticoid, impressive differ-
entiation was observed in Chub-S7 cells as assessed by markers
including FABP4, G3PD and adipocyte-speciﬁc genes such as
GLUT-4 and PPARg2. Adipogenesis was an ongoing process
upto16daysinculturewithintracellularlipidstoresconﬁrmed
by oil red O staining. No signiﬁcant changes were observed in
GRaexpressionduringthisdifferentiationphase;earlierstudies
had reported increased GR expression in omental versus
subcutaneous adipose tissue and had argued that this may be
theonefactorexplainingthepredilectionofglucocorticoidsfor
visceral obesity (Bronnegard et al.1 9 9 0 ). However, more
recently our array and real-time PCR analyses failed to
demonstrate any difference in GR expression between human
omental and subcutaneous preadipocytes (Bujalska et al.2 0 0 6 )
andadiposetissue(unpublisheddata).Together withthe datain
thisstudy, it seemsunlikelythatchangesinGRexpressionper se
are important in the adipogenesis process.
At a pre-receptor level our group has focussed on the role of
11b-HSD1 and the regeneration of cortisol from inactive
cortisone in human adipose tissue. Previously we have
demonstrated increased expression of 11b-HSD1 in omental
comparedwithsubcutaneousdepots(Bujalskaet al.19 97 b),and
importantly a switch in the directionality of enzyme activity
from predominant dehydrogenase to oxo-reductase (Bujalska
et al.2 0 0 2 a), probably as a result of induction of the NADPH
donor sourcefor11b-HSD1 within the endoplasmic reticulum
(ER) lumen, H6PDH (Ozols 1993). In support of these
observations, in this study, the rise in H6PDH mRNA levels
probably explained the increase in 11b-HSD1-mediated oxo-
reductaseactivitybetweendays3and9inadditiontoanincrease
in11b-HSD1 mRNA levels.Furthermore, decreased H6PDH
mRNAexpressionseenonday16mightaccountforthedecline
in11b-HSD1oxo-reductaseactivitydespitehighmRNA.The
impressive increase in 11b-HSD1 expression across adipocyte
differentiation has been noted recently in mouse 3T3-L1 cells
(Kim etal.2 0 0 7 ), asithasbeendoneinotherdifferentiatingcell
systems including osteoblasts (Eijken et al.2 0 0 5 ). In both cases
cells have been incubated with glucocorticoids that themselves
positively regulate 11b-HSD1 (Bujalska et al.1 9 9 7 b); it is not
possiblefromtheseor previousdatasetstoconcludewhetheror
not the increased 11b-HSD1 expression is glucocorticoid
mediated or a manifestation of the differentiation process per se.
Nevertheless,11b-HSD1expression,resultinginafunction-
allyactiveoxo-reductase,wasclearlylinkedtothedifferentiation
phenotype. Incubation of Chub-S7 cells with inactive steroid,
cortisone, induced a degree of adipocyte differentiation similar
to that observed with cortisol. This could be explained on the
basis of 11b-HSD1-mediated oxo-reductase activity with a Km
for cortisone in Chubb-S7 cells of 100 nM which is similar to
the reports in other 11b-HSD1-expressing cell systems
(Monder & Lakshmi 1989, Ricketts et al.1 9 9 8 ) including
studiesontherecombinantenzyme(KmZ333 nM;Walker etal.
2001, Shafqat et al.2 0 0 3 ). Evaluation of the competitive
11b-HSD1 inhibitor, PF-877423, indicated selectivity for
the type 1 11b-HSD isoform with a Ki£0.2n M i n t h e
recombinant assay and IC50w5 nM in Chubb-S7 cells.
Selectivityof the inhibitor towards 11b-HSD1 isoform but not
11b-HSD2 is crucial as patients with impairment in the latter
are presented with severe hypertension, (White et al.1 9 9 7 ).
Figure 5 Gene expression analysed by real-time PCR of adipogenic markers; (A) FABP4: (log scale) 2-fold increase on day 5,
38-fold on day 7, 142-fold on day 9 and 870-fold on day 16 versus day 3; (B) G3PD: 4.5-fold on day 7, 22-fold on day 9 and
380-fold on day 16 versus day 5; (C) PPARg2: 1.3-fold on day 9 and 2.2-fold on day 16 versus day 7; and (D) GLUT-4: 2.1-fold
on day 9 and 9.8-fold on day 16 versus day 7 across Chub-S7 cell differentiation. P values: **P!0.01, ***P!0.001.
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cell line expressing human 11b-HSD2 enzyme where no
inhibitoryeffect wasobserved.Incubationofcellswith100 nM
PF-877423 completely abolished the cortisone induction of
FABP4, G3PDH and 11b-HSD1 itself in Chubb-S7 cells. We
also demonstrated that the transformed cell line data were
consistent with data in primary human subcutaneous pre-
adipocytes. While incubation with cortisone yielded a less
impressive effect on adipogenesis in human subcutaneous
preadipocytes when compared with Chubb-S7 cells (this
might reﬂect a more advanced adipogenic lineage of primary
cultures),inhibitionof11b-HSD1activityneverthelessreduced
theabilityofhumansubcutaneouspreadipocytestodifferentiate
and accumulate lipid.
Whilst the cell line that we have used is subcutaneous in
origin and the expression of 11b-HSD1 is higher in omental
human preadipocytes (Bujalska et al. 1997b) and therefore we
predict that the impact upon omental cells would be more
pronounced. We anticipate that this would not lead to
preferential loss of subcutaneous fat. Unfortunately, omental
cell lines are not available for study and in vivo human clinical
studies have not been performed.
Previously, non-selective 11b-HSD inhibitors have been
shown to diminish human adipocyte differentiation in vitro
(Bujalska et al.1 9 9 9 ) and increase insulin sensitivity in man
(Walker et al.1 9 9 5 ), but a lack of isozyme selectivity can cause
waterretentionandhypertension.Sincethen,patentshavebeen
ﬁled on compounds that report to be selective 11b-HSD1
inhibitors. An aryl sulphonamide derivative has been shown to
reduce insulin levels and improve glucose tolerance when
administered to rodents for 7 days (Alberts et al.2 0 0 2 ). Similar
data have been reported for an adamantyl triazole that also
reduced body weight and the progression of atherosclerosis in
mice (Hermanowski-Vosatka et al.2 0 0 5 ). Transgenic mouse
modelshaveestablished11b-HSD1asanoveltherapeutictarget
inthisregard;global deletionof11b-HSD1 resultsinimproved
Figure 6 Chub-S7 cells differentiated with 0. 5 mM E and with or without the selective 11b-HSD1 inhibitor PF-877423 at 100 nM. All
experiments were carried out on differentiated cells on day 10, nZ3. (A) 11b-HSD1 oxo-reductase activity (cortisone to cortisol
conversion): 14.6G2.4 (E) versus 1.2G1.1( E CPF-877423) vs 3.4G1.3 (control), pmol/mg per h meanGS.E.M., P!0.001, (B) 11b-HSD1
mRNA expression and adipogenic markers (C) FABP4, (D) G3PD (log scale, P!0.001 and P!0.001 respectively) and (E) Chub-S7 cells
differentiated for 21 days and stained with oil red O; 1) control: 166 nM insulin, PPARg agonist, 100 nM PF-877423, 2) 0.5 mME ,
3) 0.5 mME C100 nM PF-877423 and 4) positive control (differentiation with 0.5 mM F). P values: **P!0.01, ***P!0.001.
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glucose output (Kotelevtsev et al.1 9 9 7 , Morton et al.2 0 0 1 ),
while targeted overexpression of 11b-HSD1 in adipose tissue
recapitulates features of the MS including central adiposity
(Masuzaki et al.2 0 0 1 ). In the liver of db/db mice (a model of
type 2 diabetes), GR and 11b-HSD1 mRNA expression
positively correlated with blood insulin and glucose (Liu et al.
2005).InhibitionofGRand11b-HSD1expressioneitherwith
GRantagonist(RU486;Liuetal.2005)orbychronicactivation
ofliverXreceptor (Liuetal.2 0 0 6 ) attenuated the phenotypeof
type 2 diabetes in mice.
In humans, the situation is less clear with regard to a role for
11b-HSD1 in the pathogenesis of MS. Some authors have
argued for a primary overexpression of 11b-HSD1 in affected
patients akin to that observed in some animal models
(Paulmyer-Lacroix et al.2 0 0 2 , Rask et al.2 0 0 2 ). However,
while the expression of 11b-HSD1 might be increased, at least
in subcutaneous adipose tissue in obese patients with MS and
type 2 diabetes (Tomlinson et al.2 0 0 2 , Alberti et al.2 0 0 7 ), no
such increase was observed in omental adipose tissue.
Furthermore, based on urinary cortisol/cortisone metabolite
ratios and plasma cortisol generation curves following oral
cortisone acetate that primarily reﬂects hepatic 11b-HSD1
expression, a reduction, not an increase, in 11b-HSD1
expression was observed at least in subjects with simple obesity
(Stewartetal.19 99 ,Tomlinson etal.20 04 ).Wehavearguedthat
obesityisnotprimarilyastateof11b-HSD1overexpression,but
thatthefallinhepatic11b-HSD1activitywithincreasedvisceral
adipositymightserveasaprotectivemechanismtooffsethepatic
glucose output and further adiposity (Valsamakis et al.2 0 0 4 ).
Failureofsuch aswitchoff in11b-HSD1expression mightbe a
factor that determines the onset and persistence of hypergly-
caemia in obese patients with type 2 diabetes mellitus
(Valsamakis et al.2 0 0 4 ). Further studies are indicated to deﬁne
the exact role of 11b-HSD1 in the pathophysiology of human
MS. Irrespective of the outcome of these studies, selective
inhibitors such as PF-877423 offer a real advance in the
prevention and treatment of diabetes in subjects with obesity
with the potential added beneﬁt of inhibiting adipocyte
differentiation. A reduction in adipogenesis speciﬁcally within
omental depots is likely to further improve the metabolic
phenotype of these patients. Clinical studies characterising a
novel, potent (Ki 0.2 nM) and fully selective 11b-HSD1
inhibitor preventing lipogenesis in vitro will further our
understanding of the role of local glucocorticoid metabolism
in human adipose tissue.
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